Shockwave Medical, Inc.

SWAVUnited States

22 filed reports · 396 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

$730M

FY2023 · to Dec 31, 2023

up +49.1% vs $490M

10-K

Net income

$147M

FY2023 · to Dec 31, 2023

down −31.8% vs $216M

10-K

Operating income

$159M

FY2023 · to Dec 31, 2023

up +28.2% vs $124M

10-K

Latest quarter

Revenue

$219M

Q1 FY2024 · to Mar 31, 2024

up +35.8% vs $161M

10-Q

Net income

$55.3M

Q1 FY2024 · to Mar 31, 2024

up +41.5% vs $39.1M

10-Q

Operating income

$42.4M

Q1 FY2024 · to Mar 31, 2024

up +6.5% vs $39.8M

10-Q

Filed reports

22 reports · Mar 2019 to Mar 2024

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Quarterly · 10-QSEC EDGAR162,571Mar 2019 to Mar 2024
Annual · 10-KSEC EDGAR52,376Dec 2019 to Dec 2023
Registration · S-1SEC EDGAR1174Nov 2019

Documents

PeriodTypePeriod endPublishedFactsSource
FY2024 Q110-Q2024-03-312024-05-06344Open
FY202310-K2023-12-312024-02-26873Open
FY2023 Q310-Q2023-09-302023-11-06267Open
FY2023 Q210-Q2023-06-302023-08-07234Open
FY2023 Q110-Q2023-03-312023-05-08134Open
FY202210-K2022-12-312023-02-27415Open
FY2022 Q310-Q2022-09-302022-11-07161Open
FY2022 Q210-Q2022-06-302022-08-08131Open
FY2022 Q110-Q2022-03-312022-05-09141Open
FY202110-K2021-12-312022-02-25430Open
FY2021 Q310-Q2021-09-302021-11-08162Open
FY2021 Q210-Q2021-06-302021-08-09118Open

Financial data

396 concepts · 5,121 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

Financial393 concepts · 4,912 facts · Dec 2017 to Mar 2024

  • Stockholders equity (US GAAP)33 · Dec 2017 to Mar 2024
  • Adjustments to additional paid in capital sharebased compensation requisite service period recognition value32 · Dec 2017 to Mar 2024
  • Capital expenditures incurred but not yet paid32 · Dec 2017 to Mar 2024
  • Cash cash equivalents restricted cash and restricted cash equivalents including disposal group and discontinued operations32 · Dec 2017 to Mar 2024
  • Cash cash equivalents restricted cash and restricted cash equivalents period increase decrease including exchange rate effect32 · Dec 2017 to Mar 2024
  • Comprehensive income net of tax32 · Dec 2017 to Mar 2024
  • Cost of goods and services sold (US GAAP)32 · Dec 2017 to Mar 2024
  • Costs and expenses32 · Dec 2017 to Mar 2024
  • General and administrative expense (US GAAP)32 · Dec 2017 to Mar 2024
  • Income loss from continuing operations before income taxes extraordinary items noncontrolling interest32 · Dec 2017 to Mar 2024
  • Income tax expense benefit32 · Dec 2017 to Mar 2024
  • Increase decrease in accounts payable32 · Dec 2017 to Mar 2024
  • Increase decrease in accounts receivable32 · Dec 2017 to Mar 2024
  • Increase decrease in accrued liabilities and other operating liabilities32 · Dec 2017 to Mar 2024
  • Increase decrease in inventories32 · Dec 2017 to Mar 2024
  • Increase decrease in prepaid deferred expense and other assets32 · Dec 2017 to Mar 2024
  • Interest expense (US GAAP)32 · Dec 2017 to Mar 2024
  • Interest paid net32 · Dec 2017 to Mar 2024
  • Net cash provided by used in financing activities32 · Dec 2017 to Mar 2024
  • Net cash provided by used in investing activities32 · Dec 2017 to Mar 2024
  • Net cash provided by used in operating activities32 · Dec 2017 to Mar 2024
  • Net income loss32 · Dec 2017 to Mar 2024
  • Operating income loss32 · Dec 2017 to Mar 2024
  • Payments to acquire property plant and equipment32 · Dec 2017 to Mar 2024

Geography2 concepts · 123 facts · Dec 2017 to Mar 2024

  • Revenue120 · Dec 2017 to Mar 2024
  • Operating Lease Liability Weighted Average Incremental Borrowing Rate3 · Mar 2019 to Dec 2020

Product1 concept · 86 facts · Dec 2018 to Mar 2024

  • Revenue86 · Dec 2018 to Mar 2024

Segments

209 facts

Figures broken down by business line, region, product or another axis the company reports on.

Statement geographical5 members · 123 facts

  • All Other Countries32 · Dec 2017 to Mar 2024
  • United States32 · Dec 2017 to Mar 2024
  • Europe22 · Dec 2019 to Mar 2024
  • Germany20 · Dec 2017 to Mar 2021
  • Rest of Europe17 · Dec 2017 to Mar 2021

Product or service5 members · 86 facts

  • Other24 · Dec 2018 to Mar 2024
  • Coronary23 · Dec 2018 to Mar 2024
  • Peripheral23 · Dec 2018 to Mar 2024
  • Reducer12 · Dec 2021 to Mar 2024
  • License4 · Mar 2021 to Mar 2022

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of Shockwave Medical, Inc. (SWAV) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.

Shockwave Medical, Inc. (SWAV): FY2023 revenue $730M · FactIQ